Technology | July 07, 2014

Vital Connect HealthPatch MD Biosensor Receives FDA Clearance

July 7, 2014 — Vital Connect announced its HealthPatch MD biosensor has received U.S. Food and Drug Administration (FDA) clearance. The solution is capable of capturing clinical-grade biometric measurements and is the first FDA-cleared medical device that includes a fall detection feature. Designed to support the treatment of a range of diseases and conditions, the HealthPatch MD is a versatile and comprehensive biosensor solution that may be used by healthcare professionals to provide 24-hour, real-time, unattended monitoring of patients’ physiological data or vital signs.

Combined with Vital Connect’s proprietary algorithms, the sensor’s technologies enable the device to provide clinical-grade measurements of the following core health metrics: single-lead ECG (electrocardiogram), heart rate, heart rate variability, respiratory rate, skin temperature, posture including fall detection and severity, and steps. The HealthPatch MD leverages on-board intelligence to perform sophisticated, proprietary SensorFusion algorithms, which process thousands of data points per minute to produce accurate robust measurements.

“We are very proud and excited that the HealthPatch MD has received FDA clearance and can now be sold in the United States for medical use,” said Vital Connect CEO Nersi Nazari. “Together with our partners, we cannot wait to begin implementing solutions using the HealthPatch MD to optimize the way healthcare is delivered in the U.S.”

Healthcare professionals will be able to use the sensor to collect patient data on demand and may be notified when physiological data falls outside selected parameters. The HealthPatch MD is intended to be less obtrusive than other sensors, can be customized for data reporting, operates on Bluetooth 4.0 and provides HIPPA-compliant cloud-based storage and connectivity.

The HealthPatch MD has received regulatory approval (CE mark) for distribution in the European Union, and is licensed and registered by Health Canada for distribution in Canada.

For more information:

Related Content

HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
Wearable monitors create patient generated health data, PGHD, that can help prevent acute care episodes in heart failure.

Wearable monitoring devices may offer a new tool to help prevent acute care episodes in heart failure.

Feature | Heart Failure| July 25, 2017 | Lola Koktysh
Despite their best efforts, many patients tend to develop heart failure after an acute event (e.g., a heart attack or
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients
News | Heart Failure| July 14, 2017
A review appearing in the July 18 issue of the Journal of the American College of Cardiology (JACC) discusses current...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Sponsored Content | Videos | Heart Failure| July 13, 2017
William Abraham, M.D., director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medica
monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

A heart failure patient wearing the SensiVest remote monitoring system for a two-minute a day assessment. 

News | Heart Failure| July 13, 2017
July 13, 2017 — About 5.7 million adults in the U.S.
Overlay Init